Hansoh Pharmaceutical Group Company Limited (HNSPF)

Market Cap	29.40B +124.0%
Revenue (ttm)	1.84B +9.0%
Net Income	667.42M +1.4%
EPS	0.11 +5.9%
Shares Out	n/a
PE Ratio	44.05
Forward PE	38.96
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	1,608
Open	4.458
Previous Close	4.458
Day's Range	4.458 - 4.458
52-Week Range	1.950 - 5.200
Beta	0.64
RSI	57.68
Earnings Date	Mar 20, 2026

About HNSPF

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Amei...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1995
• Employees: 9,313
• Stock Exchange: OTCMKTS
• Ticker Symbol: HNSPF

Financial Performance

In 2024, HNSPF's revenue was 12.26 billion, an increase of 21.35% compared to the previous year's 10.10 billion. Earnings were 4.37 billion, an increase of 33.39%.

Financial numbers in CNY